Automaker trade backs U.S. on effort to weaken fuel efficiency rules

spike

WASHINGTON (Reuters) – A group representing many major automakers on Friday backed the Trump administration’s decision to weaken Obama administration fuel efficiency standards but said it opposed further reductions in requirements.

FILE PHOTO: The Ford logo seen at the North American International Auto Show in Detroit, Michigan, U.S., January 15, 2019. REUTERS/Brendan McDermid/File Photo

In March, the Trump administration issued final rules requiring 1.5% annual increases in efficiency through 2026 – far weaker than the 5% increases in the discarded Obama-era rules – but abandoned its August 2018 proposal to freeze requirements at 2020 levels through 2026.

The Alliance for

Read More

Automaker trade opposes effort to freeze U.S. fuel efficiency standards

spike

FILE PHOTO: The Ford logo seen at the North American International Auto Show in Detroit, Michigan, U.S., January 15, 2019. REUTERS/Brendan McDermid/File Photo

WASHINGTON (Reuters) – A group representing many major automakers on Friday said it was intervening in a lawsuit that says the Trump administration did not go far enough in weakening — but not freezing — Obama administration standards to revise fuel economy standards.

In March, the Trump administration said it would require 1.5% annual increases in efficiency through 2026 — far weaker than the 5% increases in the discarded Obama era rules — but abandoned its August

Read More

Trump signs deal with company in effort shift drug manufacturing to U.S.: New York Times

spike

U.S. President Donald Trump speaks with restaurant executives and industry leaders during a coronavirus disease (COVID-19) pandemic meeting in the State Dining Room at the White House in Washington, U.S., May 18, 2020. REUTERS/Leah Millis

(Reuters) – The United States will announce on Tuesday that it has signed a $354 million contract with a company to make generic medicines and pharmaceutical ingredients in the country needed to treat COVID-19, the New York Times reported late on Monday.

The move is part of efforts to bring pharmaceutical manufacturing to the United States from abroad. Phlow Corp is a generic drug maker

Read More

Trump signs deal with company in effort shift drug manufacturing to U.S.: NYT

spike

U.S. President Donald Trump speaks with restaurant executives and industry leaders during a coronavirus disease (COVID-19) pandemic meeting in the State Dining Room at the White House in Washington, U.S., May 18, 2020. REUTERS/Leah Millis

(Reuters) – The United States will announce on Tuesday that it has signed a $354 million contract with a company to make generic medicines and pharmaceutical ingredients in the country needed to treat COVID-19, the New York Times reported late on Monday.

The move is part of efforts to bring pharmaceutical manufacturing to the United States from abroad. Phlow Corp is a generic drug maker

Read More